Figure 9.
CYP450 metabolic pathways involved in the metabolism of erythromycin and midazolam and their respective affinities for the isoform are depicted. Mechanism-based inhibition at the CYP3A4 enzymatic level will be expected. Midazolam is the victim drug and erythromycin acts as the perpetrator drug.